Mrx34 - Pharma

Relevant Publications

Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer.

Issue Release: 2021

MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.

Issue Release: 2021

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

Issue Release: 2020

MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer.

Issue Release: 2019

Expanding the Biotherapeutics Realm via miR-34a: \"Potent Clever Little\" Agent in Breast Cancer Therapy.

Issue Release: 2019

Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy.

Issue Release: 2018

Non-coding RNAs: the cancer genome dark matter that matters!

Issue Release: 2017

Cancer Hallmarks and MicroRNAs: The Therapeutic Connection.

Issue Release: 2017

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.

Issue Release: 2016

From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks.

Issue Release: 2016

MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?

Issue Release: 2016

Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology?

Issue Release: 2016

PDL1 Regulation by p53 via miR-34.

Issue Release: 2015

A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic.

Issue Release: 2015

The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Issue Release: 2015

The role of microRNAs in the resistance to colorectal cancer treatments.

Issue Release: 2015

Data integration of 104 studies related with microRNA epigenetics revealed that miR-34 gene family is silenced by DNA methylation in the highest number of cancer types.

Issue Release: 2014

Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates.

Issue Release: 2014

MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Issue Release: 2013

IL1RAPL2 maps to Xq22 and is specifically expressed in the central nervous system.

Issue Release: 2001

Why is Regulatory Approval Important?

What is Medication Adherence?

What Are the Challenges in Managing Chronic Conditions?

What are the Key Challenges?

How Do Pharmacists Contribute to Patient Care?

How Can Cellular Stress Be Measured?

What are Contract Research Organizations (CROs)?

What is an Abbreviated New Drug Application (ANDA)?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

What are the Challenges in Implementing Collaborative Care Models?

Partnered Content Networks

Relevant Topics